Fig 2: ZNF471 could interact with BANP to inhibit the activation of the PI3K/AKT/mTOR signalling pathway. A-B. Transcriptome sequencing in renal cancer cell lines overexpressing ZNF471. C. KEGG functional enrichment analyses of the differentially expressed genes. D. The anticancer effects of ZNF471 through inhibition of PI3K/AKT/mTOR activation. E. Proteins with direct interactions with ZNF471, including MIS18A, BANP and KPNA4, based on IntAct analysis. F. The proteins binding to ZNF471, including MIS18A, COG7, PHF20L1, CARD14, BANP and HAUS1, identified in the Pathway Commons database. G. The interaction between ZNF471 and BANP, as determined through STRING database analysis. H-J. The correlation between the expression of ZNF471 and BANP, as determined by qRT-PCR and Western blot analyses. K-L. ZNF471 could physically bind to BANP, as determined by a coimmunoprecipitation assay. (n.s: p>0.05, *p<0.05, **p<0.01, ***p<0.001).

Fig 3: BANP inhibited the proliferation and metastasis of renal carcinoma cells. A-B. The knockdown efficiency of BANP in renal cancer cell lines stably transfected with ZNF471. C-D. The ability of proliferation in four groups of Vector, ZNF471, ZNF471+siBANP and Vector+siBANP, as determined by a CCK-8 assay. E-F. The ability of proliferation in four groups of Vector, ZNF471, ZNF471+siBANP and Vector+siBANP, as determined by a plate colony formation assay. G-J. The ability of invasion in four groups of Vector, ZNF471, ZNF471+siBANP and Vector+siBANP, as determined by a wound healing assay. K-L. The ability of invasion in four groups of Vector, ZNF471, ZNF471+siBANP and Vector+siBANP, as determined by a Transwell assay. (n.s: p>0.05, *p<0.05, **p<0.01, ***p<0.001).